Abstract
This multicentre cohort study showed that Risankizumab is an effective induction therapy in patients with Crohn’s disease, and that the best results are obtained when Risankizumab is used as second-line therapy following a previous failure with a TNF inhibitor.
Author supplied keywords
Cite
CITATION STYLE
APA
Macaluso, F. S., Renna, S., Fries, W., Viola, A., Cappello, M., Salerno, I. A., … Orlando, A. (2025). The Effectiveness of Risankizumab as Induction Therapy for Crohn’s Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 31(4), 1178–1181. https://doi.org/10.1093/ibd/izae248
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free